M. Resnick

发表

Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

D. Bell, M. A. Resnick, J. Jordan, 2008, PLoS genetics.

Low-level p53 expression changes transactivation rules and reveals superactivating sequences

T. Haran, J. Jordan, D. Menendez, 2012, Proceedings of the National Academy of Sciences.

Functional Diversity in the Gene Network Controlled by the Master Regulator p53 in Humans

D. Bell, M. A. Resnick, D. Menendez, 2005, Cell cycle.

Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity

A. Inga, M. Resnick, 2003, Proceedings of the National Academy of Sciences of the United States of America.

p53 and NF-κB coregulate proinflammatory gene responses in human macrophages.

P. Bushel, D. Menendez, M. Shatz, 2014, Cancer research.

Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells

Johannes M. Freudenberg, Raja Jothi, Raja Jothi, 2013, Nucleic acids research.

Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity

Scott E. Martin, Eugen C. Buehler, M. A. Resnick, 2022, Oncotarget.

Mutant TP53 Posttranslational Modifications: Challenges and Opportunities

C. Anderson, D. Menendez, Thuy-Ai T Nguyen, 2014, Human mutation.

Modulation of immune responses by the tumor suppressor p53

D. Menendez, M. Shatz, Julie M. Lowe, 2013 .

Interactions between the tumor suppressor p53 and immune responses

D. Menendez, M. Shatz, M. Resnick, 2013, Current opinion in oncology.

OPINION Interactions between the tumor suppressor p53 and immune responses

D. Menendez, M. Shatz, M. Resnick, 2013 .

Transactivation by low and high levels of human p53 reveals new physical rules of engagement and novel super-transactivation sequences

T. Haran, M. A. Resnick, D. Menendez, 2012, Cell cycle.

The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.

D. Menendez, M. Shatz, M. Resnick, 2012, Cancer research.

Dominant-Negative Features of Mutant TP53 in Germline Carriers Have Limited Impact on Cancer Outcomes

A. Inga, P. Monti, G. Fronza, 2011, Molecular Cancer Research.

limited impact on cancer outcomes.

A. Inga, P. Monti, G. Fronza, 2011 .

Cancer Genes and Genomics Dominant-Negative Features of Mutant TP 53 in Germline Carriers Have Limited Impact on Cancer Outcomes

A. Inga, P. Monti, G. Fronza, 2011 .

Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation

L. Carey, J. Jordan, A. Inga, 2010, Molecular Cancer Research.

The p53 Master Regulator and Rules of Engagement with Target Sequences

M. A. Resnick, J. Jordan, D. Menendez, 2010 .

The expanding universe of p53 targets

Alberto Inga, M. A. Resnick, D. Menendez, 2009, Nature Reviews Cancer.

A Regulatory Loop Composed of RAP80-HDM2-p53 Provides RAP80-enhanced p53 Degradation by HDM2 in Response to DNA Damage*

D. Menendez, A. Jetten, Xiao‐ping Yang, 2009, The Journal of Biological Chemistry.

Probing the Functional Impact of Sequence Variation on p53-DNA Interactions Using a Novel Microsphere Assay for Protein-DNA Binding with Human Cell Extracts

Douglas A. Bell, Brian N. Chorley, Michelle R. Campbell, 2009, PLoS genetics.

The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes

Alberto Inga, M. A. Resnick, D. Menendez, 2006, Molecular and Cellular Biology.

Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay

J. Jordan, A. Inga, Vasundhara Sharma, 2015, PloS one.

Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis

D. Bell, M. Horvath, Xuting Wang, 2007, PLoS genetics.

Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences

D. Menendez, A. Inga, M. Resnick, 2010, Proceedings of the National Academy of Sciences.

Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics

M. A. Resnick, D. Menendez, A. Inga, 2013, Cell cycle.

Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence

Francesca Storici, Thomas A. Darden, Alberto Inga, 2002, Molecular and Cellular Biology.

Yeast and human genes that affect the Escherichia coli SOS response.

J. Sterling, V. Hashem, E. Perkins, 1999, Proceedings of the National Academy of Sciences of the United States of America.

The novel p53 target TNFAIP8 variant 2 is increased in cancer and offsets p53-dependent tumor suppression

Sara A. Grimm, Leping Li, S. Peddada, 2016, Cell Death and Differentiation.

Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson

J. Jordan, D. Menendez, A. Inga, 2007, Oncogene.

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements

R. Iggo, T. Crook, M. A. Resnick, 2001, Oncogene.

Human Macrophages B Coregulate Proinflammatory Gene Responses in κ p 53 and NF-Updated

P. Bushel, D. Menendez, M. Shatz, 2014 .

Microenvironment and Immunology p 53 and NFk B Coregulate Proin fl ammatory Gene Responses in Human Macrophages

P. Bushel, D. Menendez, M. Shatz, 2014 .

Responses in Human Macrophages

P. Bushel, D. Menendez, M. Shatz, 2014 .

ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells1

D. Menendez, Y. Ciribilli, L. Pezzè, 2018, Neoplasia.

The Toll-Like Receptor Gene Family Is Integrated into Human DNA Damage and p53 Networks

D. Menendez, M. Shatz, M. Fessler, 2011, PLoS genetics.

The Shu complex promotes error-free tolerance of alkylation-induced base excision repair products

Stephen K. Godin, Benjamin W Herken, Kara A. Bernstein, 2016, Nucleic acids research.

The Coordinated P53 and Estrogen Receptor Cis-Regulation at an FLT1 Promoter SNP Is Specific to Genotoxic Stress and Estrogenic Compound

D. Menendez, A. Inga, Y. Ciribilli, 2010, PloS one.

Revealing a human p53 universe

Brian D. Bennett, Christopher A. Lavender, Sara A. Grimm, 2018, Nucleic acids research.

A multistep genomic screen identifies new genes required for repair of DNA double-strand breaks in Saccharomyces cerevisiae

M. Resnick, J. Westmoreland, L. K. Lewis, 2013, BMC Genomics.

A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network

D. Menendez, A. Inga, G. Schönfelder, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.

Michelle R. Campbell, D. Bell, G. Pittman, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells

D. Menendez, Julie M. Lowe, J. Snipe, 2016, Oncotarget.

A Single-Nucleotide Polymorphism in a Half-Binding Site Creates p53 and Estrogen Receptor Control of Vascular Endothelial Growth Factor Receptor 1

D. Menendez, A. Inga, G. Schönfelder, 2007, Molecular and Cellular Biology.

A SNP in a half-binding site creates p53 and estrogen receptor control of VEGFR-1

D. Menendez, A. Inga, G. Schönfelder, 2007 .

The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53

D. Menendez, Thuy-Ai T Nguyen, J. Snipe, 2017, Molecular Cancer Research.

Oncogenes and Tumor Suppressors The Cytidine Deaminase APOBEC 3 Family Is Subject to Transcriptional Regulation by p 53

D. Menendez, Thuy-Ai T Nguyen, J. Snipe, 2017 .

Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code

D. Menendez, A. Inga, P. Monti, 2013, Nucleic acids research.

Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants

Alberto Inga, M. A. Resnick, A. Inga, 2001, Oncogene.

Functional evolution of the p53 regulatory network through its target response elements

B. Aronow, A. Jegga, D. Menendez, 2008, Proceedings of the National Academy of Sciences.

A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions

S. Velasco-Miguel, A. Inga, E. Friedberg, 2002, Oncogene.

Tumour p53 mutations exhibit promoter selective dominance over wild type p53

A. Inga, P. Monti, G. Fronza, 2002, Oncogene.

p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay

T. Darden, M. A. Resnick, A. Inga, 2001, Oncogene.

Potentiating the p53 network.

D. Menendez, A. Inga, M. Resnick, 2010, Discovery medicine.

Increased LOH Due to Defective Sister Chromatid Cohesion Is Due Primarily to Chromosomal Aneuploidy and Not Recombination

S. Covo, M. A. Resnick, V. K. Bari, 2017, G3: Genes, Genomes, Genetics.

A Novel Role in DNA Metabolism for the Binding of Fen1/Rad27 to PCNA and Implications for Genetic Risk

D. Gordenin, M. A. Resnick, J. Nolan, 1999, Molecular and Cellular Biology.

DANIel MeNeNDez , A lber To INgA , AND MIchAel A. r eSNIck

M. A. Resnick, D. Menendez, A. Inga, 2010 .

p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways

D. Menendez, M. Shatz, I. Shats, 2015, Oncotarget.

RAP80 is critical in maintaining genomic stability and suppressing tumor development.

J. French, M. A. Resnick, D. Menendez, 2012, Cancer research.

Lack of DNA homology in a pair of divergent chromosomes greatly sensitizes them to loss by DNA damage.

M. Skaanild, T. Nilsson‐Tillgren, M. Resnick, 1989, Proceedings of the National Academy of Sciences of the United States of America.

DNA fragment mass distributions following molecular recombination

T. Darden, M. Resnick, 1985, Advances in Applied Probability.

Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype

L. Luzzatto, J. Jordan, A. Inga, 2007, Clinical Cancer Research.

p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System

J. Jordan, A. Inga, P. Monti, 2011, PloS one.

p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus.

F. Polack, D. Menendez, C. Innes, 2019, The Journal of clinical investigation.

Functional dissection of sequence-specific NKX2-5 DNA binding domain mutations associated with human heart septation defects using a yeast-based system.

J. Borlak, M. A. Resnick, A. Inga, 2005, Human molecular genetics.

p53 integrates host defense and cell fate during bacterial pneumonia

P. Bushel, Leping Li, M. A. Resnick, 2013, The Journal of experimental medicine.

Understanding the complex crosstalk between p53 and the estrogen receptors at a polymorphic variant of the VEGF receptor Flt-1 promoter

D. Menendez, A. Inga, Y. Ciribilli, 2008 .

60 Binding and transactivation by the tumor suppression protein p53 are encoded in the differential structural properties of its response elements

T. Haran, J. Jordan, D. Menendez, 2013 .

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

D. Bell, M. A. Resnick, J. Jordan, 2008, PLoS Genetics.

Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays.

B H Margolin, J K Haseman, E Zeiger, 1987, Science.

Mutant TP53 Posttranslational Modifications: Challenges and Opportunities

C. Anderson, D. Menendez, Thuy-Ai T Nguyen, 2014, Human mutation.

Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays.

R. Tennant, J. Spalding, S. Stasiewicz, 1987, Science.

APOBEC3G Is a p53-Dependent Restriction Factor in Respiratory Syncytial Virus Infection of Human Cells Included in the p53/Immune Axis

D. Menendez, S. Kleeberger, W. Gladwell, 2023, International Journal of Molecular Sciences.

Interactions between the tumor suppressor p53 and immune responses

D. Menendez, M. Shatz, M. Resnick, 2013, Current opinion in oncology.

p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways

D. Menendez, M. Shatz, I. Shats, 2015, Oncotarget.